


Currently available epinephrine delivery methods:



Product size is not indicative of clinical efficacy nor is it intended to be a comparison of clinical efficacy or safety.

Source for device dimensions: references 1-4.

*Representative of Adrenaclick[®], which is an epinephrine auto-injector.

All trademarks and logos are the property of their respective owners.



Auvi-Q
epinephrine injection, USP
0.1 mg/0.15 mg/0.3 mg auto-injectors
No A/B-rated generic



Epinephrine Injection, USP Auto-Injector

Authorized generic



EpiPen® **EpiPen Jr**®
epinephrine injection, USP/Auto-Injectors 0.3/0.15mg

EpiPen/EpiPen Jr and AB-rated generics
Mylan-authorized generic
Teva A/B-rated generic



	Nasal spray		Needle injector			Needle injector		Needle injector	
METHOD OF ADMINISTRATION	Nasal spray		Needle injector			Needle injector		Needle injector	
DOSE	1 mg	2 mg	0.1 mg	0.15 mg	0.3 mg	0.15 mg	0.3 mg	0.15 mg	0.3 mg
PATIENT WEIGHT IN INDICATION	33-66 lbs (15-30 kg)	≥66 lbs (≥30 kg)	16.5-33 lbs (7.15-15 kg)	33-66 lbs (15-30 kg)	≥66 lbs (≥30 kg)	33-66 lbs (15-30 kg)	≥66 lbs (≥30 kg)	33-66 lbs (15-30 kg)	≥66 lbs (≥30 kg)
EXPOSED NEEDLE LENGTH	N/A		7.4 mm	12.7 mm	15.8 mm	13 mm	13.2 mm	13 mm	14.7 mm
DEVICE DIMENSIONS	2.25 x 1.75 x 0.75 in (5.72 x 4.45 x 1.91 cm)		3.38 x 2 x 0.63 in (8.59 x 5.08 x 1.60 cm)			Varies by auto-injector		6 x 1 x 0.75 in (15.24 x 2.54 x 1.91 cm)	
ADDITIONAL INGREDIENTS	Sodium chloride, n-dodecyl beta-D-maltoside, benzalkonium chloride, disodium edetate, sodium metabisulfite, hydrochloric acid or sodium hydroxide to adjust pH, water for injection		Sodium chloride, sodium bisulfite, hydrochloric acid to adjust pH, water for injection			Sodium chloride, chlorobutanol, sodium bisulfite, hydrochloric acid and sodium hydroxide to adjust pH, water for injection		Sodium chloride, sodium metabisulfite, hydrochloric acid to adjust pH, water for injection	
STORAGE/HEAT TOLERABILITY	Store at 68° to 77°F (20° to 25°C). Excursions permitted up to 122°F (50°C). [†]		Store at 68° to 77°F (20° to 25°C). Excursions permitted from 59° to 86°F (15° to 30°C).			Store at 68° to 77°F (20° to 25°C). Excursions permitted from 59° to 86°F (15° to 30°C).		Store at 68° to 77°F (20° to 25°C). Excursions permitted from 59° to 86°F (15° to 30°C).	
	See references 1 and 5		See references 2, 6, 7, and 8			See references 3, 8, and 9		See references 4, 8, and 10	

[†]Do not freeze. **neffy** freezes below 5°F (-15°C). If **neffy** freezes, it will not deliver epinephrine.

All trademarks and logos are the property of their respective owners.

This chart is not indicative of clinical efficacy nor is it intended to be a comparison of clinical efficacy or safety.

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.

IMPORTANT SAFETY INFORMATION

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

Please see full [Prescribing Information](#) for **neffy**.

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two **neffy** nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of **neffy** in the same nostril with a new nasal spray starting 5 minutes after the first dose.

Please see full [Prescribing Information](#) for **neffy**.





Scan the code
or visit neffyPRO.com

to request a **neffy** demo kit and watch a video about administering needle-free epinephrine

IMPORTANT SAFETY INFORMATION (cont)

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of **neffy** may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in **neffy** should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including **neffy**.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson's disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of **neffy**. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at **1-877-MY-NEFFY (877-696-3339)** or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full [Prescribing Information](#) for **neffy**.

References: **1.** Data on file. **neffy** value advisory board. ARS Pharmaceuticals Operations, Inc. 2022. **2.** Auvi-Q Epinephrine Auto-Injector Device. Mountainside Medical Equipment. Accessed January 21, 2025. <https://www.mountainside-medical.com/products/auvi-q-epinephrine-auto-injector>. **3.** Data on file. ARS Pharmaceuticals Operations, Inc. 2023. **4.** Epinephrine Auto Injector Training Device. Red Cross. Accessed January 21, 2025. <https://www.redcross.org/store/epinephrine-auto-injector-training-device/765201.html>. **5.** **neffy** [prescribing information]. San Diego, CA: ARS Pharmaceuticals Operations, Inc. **6.** Auvi-Q [prescribing information]. Richmond, VA: kaleo, Inc. **7.** *Needle Length Animation Video*. Auvi-Q. Accessed January 21, 2025. <https://www.auvi-q.com/hcp/resources?video=380835829#videos>. **8.** Greenberger PA, Wallace DV, Lieberman PL, Gregory SM. Contemporary issues in anaphylaxis and the evolution of epinephrine autoinjectors: what will the future bring? *Ann Allergy Asthma Immunol.* 2017;119(4):333-338. **9.** Epinephrine injection, USP auto-injector [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC. **10.** EPIPEN [prescribing information]. Morgantown, WV: Mylan Inc., a Viatris Company.



©2025 ARS Pharmaceuticals Operations, Inc. All rights reserved. "ARS Pharma," the ARS Pharma logo design, "**neffy**," and the **neffy** logo are trademarks or registered trademarks of ARS Pharmaceuticals Operations, Inc. NEF-US-0293-11 03/2025

